Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma
暂无分享,去创建一个
T. Luider | H. Avet-Loiseau | N. V. D. van de Donk | J. Jacobs | Y. D. de Rijke | I. Nijhof | M. Zajec | C. Stege | Martijn M. van Duijn | Kristine A. Frerichs
[1] L. Lampson. Editorial: Immunotherapy for Tumor in the Brain: Insights From—and For—Other Tumor Sites , 2018, Front. Oncol..
[2] M. Farrell,et al. Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab , 2018, Clinical case reports.
[3] T. Luider,et al. Development of a Targeted Mass-Spectrometry Serum Assay To Quantify M-Protein in the Presence of Therapeutic Monoclonal Antibodies. , 2018, Journal of proteome research.
[4] S. Lonial,et al. Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma , 2017, Clinical pharmacology and therapeutics.
[5] H. Goldschmidt,et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. , 2016, Blood.
[6] S. Lonial,et al. Central nervous system involvement by multiple myeloma: A multi‐institutional retrospective study of 172 patients in daily clinical practice , 2016, American journal of hematology.
[7] S. Croockewit,et al. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA) , 2016, Clinical chemistry and laboratory medicine.
[8] T. Plesner,et al. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference , 2016, Clinical chemistry and laboratory medicine.
[9] P. Moreau,et al. How I treat extramedullary myeloma. , 2016, Blood.
[10] S. Trudel,et al. Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents , 2013, British journal of haematology.
[11] P. Ho,et al. Central nervous system multiple myeloma – potential roles for intrathecal therapy and measurement of cerebrospinal fluid light chains , 2013, British journal of haematology.
[12] V. Montefusco,et al. Effective treatment of pomalidomide in central nervous system myelomatosis , 2013, Leukemia & lymphoma.
[13] M. Rolfe,et al. Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib , 2006, Molecular Cancer Therapeutics.
[14] Y. Ikeda,et al. Thalidomide for the treatment of leptomeningeal multiple myeloma , 2006 .
[15] G. Tibbling,et al. Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. , 1977, Scandinavian journal of clinical and laboratory investigation.